Opinion|Videos|March 24, 2025
Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
Panelists discuss how medical professionals balance maximizing progression-free survival with preserving future treatment options by considering disease biology, resistance mechanisms, and patient factors. At first progression, the NCCN recommends continuing current therapy or switching to amivantamab with a platinum doublet, based on mutation status, prior response, toxicity, and patient preferences.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you weigh the benefits of selecting therapies that maximize progression-free survival against the importance of preserving future treatment options?
- At first progression, NCCN recommends either continuing the patient’s current systemic therapy or changing therapy to amivantamab combined with a platinum doublet. What are the most important clinical factors to consider when making this decision?
Advertisement
Related to this article
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.
OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
First-Line CNS Efficacy in EGFR-Mutated NSCLC: FLAURA2 and MARIPOSA Data
5